Communiqués Nurix Therapeutics, Inc.

Actions

NRIX

US67080M1036

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
22,35 ^USD	+0,63%		-2,78%	+17,82%

07/10	Nurix annonce l’inclusion du premier patient dans une étude de phase 1b/2 sur une association destinée à traiter la leucémie lymphoïde	MT
07/10	Nurix Therapeutics, Inc. inclut le premier patient dans l’étude de phase 1b/2 NX-5948-203 évaluant le bexobrutideg en association avec le vénétoclax	CI

Communiqués

07/10	Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia	AQ
05/10	Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences	AQ
29/09	Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer	AQ
01/09	Nurix Therapeutics to Participate in Upcoming September Investor Conferences	AQ
20/08	Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer	AQ
04/08	Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader	AQ
04/08	Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AQ
21/07	Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology	AQ
09/07	Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	GL
11/06	Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy	AQ
08/06	Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology	AQ
14/05	Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting	AQ
13/05	Nurix Therapeutics to Participate in Upcoming Investor Conferences	AQ
12/05	Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress	AQ
22/04	Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026	GL
08/04	Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update	GL
07/04	Nurix Therapeutics to Participate in Upcoming Investor Conference	AQ
27/03	Nurix Therapeutics : 2026 Proxy Statement vF (20260327)	PU
23/03	Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting	GL
28/01	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update	AQ
12/01	Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases	AQ
05/01	Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference	AQ
08/12	Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition	AQ
06/12	Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition	AQ
01/12	Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition	AQ